



IP4 R PCT/PTO 12 JAN 2006

Attorney Docket No.: 1396-1-011PCT/US

#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Peter Knox, et al.
SERIAL NO.: 10/540,645 EXAMINER: Unassigned
DATE FILED: June 24, 2005 ART UNIT: 1615
FOR: PIPERIDINYL-THIAZOLE, CARBOXYLIC ACID
DERIVATIVES AS ANGIOGENESIS INHIBITORS

CERTIFICATE OF MAILING UNDER 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Mail Stop Amendment, Commissioner For Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on January 9, 2006.

Karen Garipoli
(Name of Depositor)

Karen Garipoli 1/9/06
(Signature and Date)

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT

In accordance with Applicant's and Applicant's representatives' Duty of Disclosure under 37 CFR § 1.56, and pursuant to 37 CFR §1.97 and MPEP 717.05(b), Applicant(s) submit herewith documentary information for consideration by the Examiner. Information herein cited is only set forth in fulfillment of Applicant's duty of candor in disclosing all information brought to his attention, and is not an admission that it can be used adversely. The publications forwarded herewith are listed on the enclosed Form PTO-1449. Applicant(s) request that the Examiner, upon reviewing the enclosed materials, initial the enclosed form and return a copy thereof in accordance with the instructions on the form.



Attorney Docket No.: 1396-1-011PCT/US

Enclosed please find copies of References **AA** through **DG** listed on the attached Form PTO-1449. No fee is believed due for the filing of this statement inasmuch as it is being filed before the mailing of the first official action on the merits. However, should the Patent and Trademark Office determine otherwise, authorization is hereby given to charge Deposit Account No. 11-1153 for this filing.

Respectfully submitted,

DAVID A. JACKSON
Attorney for Applicants
Registration No. 26,742

KLAUBER & JACKSON LLC
411 Hackensack Avenue, 4TH Floor
Hackensack, New Jersey 07601
201-487-5800



| | | |
|--|---------------------|-------------------|
| Form PTO-1449 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office | ATTORNEY DOCKET NO. | 1396-1-011PCT/US |
| | SERIAL NO. | 10/540,645 |
| LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary) | APPLICANT | Peter Knox et al. |
| | FILING DATE | June 24, 2005 |
| | GROUP | 1615 |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLAS S | SUB-CLASS | FILING DATE IF APPROPRIATE |
|------------------|----|-----------------|---------|---------------|--------|-----------|----------------------------|
| | AA | 3,966,748 | 6/29/76 | Hofmann et al | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | COUNTRY | CLAS S | SUB-CLASS | TRANSLATION YES NO |
|--|----|-----------------|---------|---------|--------|-----------|--------------------|
| | BA | WO 95/33050 | 12/7/95 | PCT | | | |
| | BC | WO 99/00356 | 1/7/99 | PCT | | | |


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|---|
| CA | Lu, Ming, et al, Vascular endothelial growth factor gene regulation and action in diabetic retinopathy, 2002, Ophthalmol Clin N Am 15; Pgs. 69-79 |
| CB | Weidner, N, et al, Tumor Angiogenesis and Metastasis-Correlation In Invasive Breast Carcinoma 1991, The New England Journal of Medicine, Vol 324; No. 1: Pgs. 1-8 |
| CC | Moen,M,etal,The familial risk of endometriosis,1993,Acta Obstet Gynecol Scand 72 Pgs 560-564 |
| CD | Blann, A, et al, Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, orType II diabetes, 2002, Clinical Science, 102, Pgs. 187-194 |
| CE | Slaton, JW, et al, Expression Levels of Genes that Regulate Metastasis and Angiogenesis Correlate with Advanced Pathological Stage of Renal Cell Carcinoma, 2001, Amer Jour of Path, Vol 158, No. 2: Pgs. 735-743 |
| CF | Thomas, EJ, et al, The aetiology and pathogenesis of endometriosis, 1992, Reproductive Med Review, 1:Pgs. 21-36 |
| CG | Noma, H, et al, Regulation of Angiogenesis in Diabetic Retinopathy, Possible Balance Between Vascular Endothelial Growth Factor and Endostatin, 2002, Arch Opth, Vol 120, Pgs. 1075-1080 |
| CH | Ferrara,N,etal,Pituitary Follicular Cells Secrete A Novel Heparin-Binding Growth Factor Specific For Vascular Endothelial Cells, 1989, Biochem&Biophys Research Comm;Vol 161, pgs. 851-858 |

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



| | |
|--|--|
| Form 101-101 IRSY. 7.801 U.S. Department of Commerce Patent and Trademark Office | ATTORNEY, DOCKET NO. 1396-1-011PCT/US |
| LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary) | SERIAL NO. 10/540,645 |
| | APPLICANT Peter Knox et al. |
| | FILING DATE June 24, 2005 |
| | GROUP 1615 |


OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | |
|----|---|
| CI | Creamer,D, etal, Mediation of Systemic Vascular Hyperpermeability in Severe Psoriasis by Circulating Vascular Endothelial Growth Factor, 2002, Arch Dermatology, Vol 138, Pgs. 791-796 |
| CJ | Klagsbrun,M,etal,VEGF/VPT the angiogenesis factor found?,1993, Curr Biol, Vol 3,No 10;Pg 699-702 |
| CK | Adams,J, etal, Vascular Endothelial Growth Factor (VEGF) in Breast Cancer:Comparison of Plasma, Serum, and Tissue VEGF and Microvessel Density and Effects of Tamoxifen ¹ , 2000, Cancer Research 60, Pgs. 2898-2905 |
| CL | Inoue, K, etal, The Prognostic Value of Angiogenesis Factor Expression for Predicting Recurrence and Metastasis of Bladder Cancer after Neoadjuvant Chemotherapy and Radical Cystectomy ¹ , 2000, Clinical Cancer Research, Vol 6, Pgs. 4866-4873 |
| CM | Borre, M, etal, Association Between Immunohistochemical Expression of Vascular Endothelial Growth Factor (VEGF), VEGF-expressing Neuroendocrine-differentiated Tumor Cells, and Outcome in Prostate Cancer Patients Subjected to Watchful Wating ¹ , 2000,Clin Cancer Res, 6, Pgs. 1882-1890 |
| CN | Shih, CH, etal, Vascular Endothelial Growth Factor Expression Predicts Outcome and Lymph Node Metastasis in Squamous Cell Carcinoma of the Esophagus ¹ , 2000, Clin Cancer Res., 6; Pgs 1161-68 |
| CO | Kaya, M etal, Vascular Endothelial Growth Factor Expression in Untreated Osteosarcoma Is Predictive of Pulmonary Metastasis and Poor Prognosis ¹ , 2000, Clin Cancer Res., 6: Pgs. 572-577 |
| CP | Tabone, MD, etal, Are Basic Fibroblast Growth Factor and Vascular Endothelial Growth Factor Prognostic Indicators in Pediatric Patients with Malignant Solid Tumors?, 2001, Clinical Cancer Research., 6, Pgs. 538-543 |
| CQ | Cascinu, S, etal, Expression of Vascular Endothelial Growth factor Can Predict Event-free Survival in Stage II Colon Cancer, 2000, Clinical Cancer Research, 6: Pgs. 2803-2807 |
| CR | Aiello, LP, Vascular Endothelial Growth Factor and the Eye:Biochemical Mechanisms of Action and Implications for Novel Therapies, 1997, Ophthalmic Res., 29: Pgs. 354-362 |
| CS | Treloar, SA, etal, Genetic influences on endometriosis in an Australian twin sample, 1999, Fertility and Sterility, Vol 71, No. 4, Pgs. 701-710 |
| CT | Afuwape, AO, etal, The role of the angiogenic molecule VEGF in the pathogenesis of rheumatoid arthritis, 2002, Histology and Histopathology, 17: Pgs. 961-972 |
| CU | Folkman, J, What is the Evidence That Tumors Are Angiogenesis Dependent?, 1990, Journal of the National Cancer Institute; Vol 82, No.1, 3 pages |
| CV | Dvorak, HF, etal, Induction of a Fibrin-Gel Investment: An Early Event in Line 10 Hepatocarcinoma Growth Mediated by Tumor-Secreted Products ¹ , 1979, Journal of Immun, 122: Pgs. 166-174 |

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



| | | |
|--|----------------------|-------------------|
| Form 1010-1015 U.S. Department of Commerce Patent and Trademark Office LIST OF DOCUMENTARY INFORMATION CITED BY APPLICANT (Use several sheets if necessary) | ATTORNEY, DOCKET NO. | 1396-1-011PCT/US |
| | SERIAL NO. | 10/540,645 |
| | APPLICANT | Peter Knox et al. |
| | FILING DATE | June 24, 2005 |
| | GROUP | 1615 |

OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|----|---|
| | CW | Shen, GH, etal, Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma, 2000, British Journal of cancer, 83(2); Pgs. 196-203 |
| | CX | Loncaster, JA, etal, Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix, 2000, British Journal of Cancer, 83(5): Pgs. 620-625 |
| | CY | Mineta,H, etal, Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas, 2000, British Journal of Cancer, 83(6): Pgs. 775-781 |
| | CZ | Yudoh, K, etal, Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas, 2001, British Jour of Cancer, 84(12): Pgs. 1610-1615 |
| | DA | Funatsu,H, etal, Prediction of macular edema exacerbation after phacoemulsification in patients with nonproliferative diabetic retinopathy, 2002, J Cataract Refract Surg; 28:Pgs. 1355-1363 |
| | DB | Abdulrauf, Saleem I, etal, Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma, 1998, J .Neurosurg 88: Pgs. 513-520 |
| | DC | Tilton, R, Diabetic Vascular Dysfunction: Links to Glucose-Induced Reductive Stress and VEGF, 2002, Microscopy Research and Technique 57: Pgs. 390-407 |
| | DD | Folkman, J., etal, Angiogenesis, 1992, The Jour of Biol Chem, Vol 267, No. 16; Pgs. 10931-10934 |
| | DE | Kennedy, S, etal, Genetics - Familial Endometriosis*, 1995, Jour of Assist Reproduct and Genetics, Vol 12, No.1, Pgs. 32-34 |
| | DF | Vaisman, N, etal, Characterization of the Receptors for Vascular Endothelial Growth Factor*, 1990, The Journal of Biological Chemistry, Vol 265, No. 32: Pgs. 19461-19466 |
| | DG | Malinak, LR, etal, Heritable aspects of endometriosis, 1980, Am. J. Obstet. Gynecol, Vol. 137, No. 3, Pgs. 332-337 |
| | | |
| | | |
| | | |
| | | |
| | | |

EXAMINER:

DATE CONSIDERED:

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.